Clinical Trials Directory

Trials / Unknown

UnknownNCT03619694

Role of MR Spectroscopy in Brain Tumors

Role of Magnetic Resonance Spectroscopy in Differentiating Brain Tumors

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers

Summary

In order to come as close as possible to the correct diagnosis of CNS tumors, MRI is the long-standing accepted method of choice that can in some cases be supported by the use of CT to demonstrate calcification or bone destruction. In individual cases MRI spectroscopy can be helpful for the differentiation between neoplasms and inflammatory lesions or surveillance of tumor therapy, just as perfusion

Detailed description

Proton magnetic resonance spectroscopy (H-MRS) may be helpful in suggesting tumor histology and tumor grade and may better define tumor extension and the ideal site for biopsy compared with conventional magnetic resonance (MR) imaging. A multifunctional approach with diffusion-weighted imaging, perfusion-weighted imaging, and permeability maps, along with H-MRS, may enhance the accuracy of the diagnosis and characterization of brain tumors and estimation of therapeutic response. Integration of advanced imaging techniques with conventional MR imaging and the clinical history help to improve the accuracy, sensitivity, and specificity in differentiating tumors and nonneoplastic lesions.

Conditions

Interventions

TypeNameDescription
DEVICEMRI SpectroscopyPatient with brain SOL underwent MRI Spectroscopy to be compared with later pathology

Timeline

Start date
2017-09-01
Primary completion
2018-09-01
Completion
2018-10-01
First posted
2018-08-08
Last updated
2018-08-08

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03619694. Inclusion in this directory is not an endorsement.